ARLTS1 variants and melanoma risk

International Journal of Cancer

Volumn 119, Issue 7, 2006, Pages 1736-1737

  Frank, Bernd ^a   Meyer, Peter ^b,c   Boettger, Melanie Barbara ^b,c   Hemminki, Kari ^a,d   Stapelmann, Henrike ^b   Gast, Andreas ^a   Schmitt, Christina ^b   Kumar, Rajiv ^a,d   Sergi, Consolato ^e   Burwinkel, Barbara ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c Genefinder Technologies Beteiligungs GmbH   (Germany)

^d KAROLINSKA INSTITUTE   (Sweden)

^e UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

Author keywords

Cancer risk; Melanoma; Multiple melanomas; Polymorphism; Tumor suppressor gene

Indexed keywords

ADENOSINE DIPHOSPHATE RIBOSYLATION; ADOLESCENT; ADULT; AGED; ARLTS1 GENE; ARTICLE; CANCER PATIENT; CANCER RISK; CHILD; FAMILIAL DISEASE; FEMALE; GENDER; GENETIC PREDISPOSITION; GENETIC VARIABILITY; HETEROZYGOSITY; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; MULTIGENE FAMILY; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ADOLESCENT; ADP-RIBOSYLATION FACTORS; ADULT; AGED; AGED, 80 AND OVER; CHILD; FEMALE; GENOTYPE; HUMANS; MALE; MELANOMA; MIDDLE AGED; RISK FACTORS; VARIATION (GENETICS);

EID: 33747514856     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.22008     Document Type: Article

References (9)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003;53:5-26.
2. Hayward NK. Genetics of melanoma predisposition. Oncogene 2003;22:3053-62.
3. Calin GA, Trapasso F, Shimizu M, Dumitru CD, Yendamuri S, Godwin AK, Ferracin M, Bernardi G, Chatterjee D, Baldassarre G, Rattan S, Alder H et al. Familial cancer associated with a polymorphism in ARLTS1. N Engl J Med 2005;352:1667-76.
4. Frank B, Klaes R, Burwinkel B. Familial cancer and ARLTS1. N Engl J Med 2005;353:313-4.
5. Frank B, Hemminki K, Meindl A, Wappenschmidt B, Klaes R, Schmutzler RK, Untch M, Bugert P, Bartram CR, Burwinkel B. Association of the ARLTS1 Cys148Arg variant with familial breast cancer risk. Int J Cancer 2006;118:2505-8.
6. Meyer P, Klaes R, Schmitt C, Boettger MB, Garbe C. Exclusion of BRAFV599E as a melanoma susceptibility mutation. Int J Cancer 2003;106:78-80.
7. Frank B, Hemminki K, Wirtenberger M, Bermejo JL, Bugert P, Klaes R, Schmutzler RK, Wappenschmidt B, Bartram CR, Burwinkel B. The rare ERBB2 variant Ile654Val is associated with an increased familial breast cancer risk. Carcinogenesis 2005;26:643-7.
8. Comings DE, MacMurray JP. Molecular heterosis: a review. Mol Genet Metab 2000;71:19-31.
9. Lehrnbecher T, Bernig T, Hanisch M, Koehl U, Behl M, Reinhardt D, Creutzig U, Klingebiel T, Chanock SJ, Schwabe D. Common genetic variants in the interleukin-6 and chitotriosidase genes are associated with the risk for serious infection in children undergoing therapy for acute myeloid leukemia. Leukemia 2005;19:1745-50.